Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Recommendations for the pharmacological management of neuropathic pain: an overview and literature update Dworkin RH; O'Connor AB; Audette J; Baron R; Gourlay GK; Haanpaa ML; Kent JL; Krane EJ; Lebel AA; Levy RM; Mackey SC; Mayer J; Miaskowski C; Raja SN; Rice AS; Schmader KE; Stacey B; Stanos S; Treede RD; Turk DC; Walco GA; Wells CDMayo Clin Proc 2010[Mar]; 85 (3 Suppl): S3-14The Neuropathic Pain Special Interest Group of the International Association for the Study of Pain recently sponsored the development of evidence-based guidelines for the pharmacological treatment of neuropathic pain. Tricyclic antidepressants, dual reuptake inhibitors of serotonin and norepinephrine, calcium channel alpha(2)-delta ligands (ie, gabapentin and pregabalin), and topical lidocaine were recommended as first-line treatment options on the basis of the results of randomized clinical trials. Opioid analgesics and tramadol were recommended as second-line treatments that can be considered for first-line use in certain clinical circumstances. Results of several recent clinical trials have become available since the development of these guidelines. These studies have examined botulinum toxin, high-concentration capsaicin patch, lacosamide, selective serotonin reuptake inhibitors, and combination therapies in various neuropathic pain conditions. The increasing number of negative clinical trials of pharmacological treatments for neuropathic pain and ambiguities in the interpretation of these negative trials must also be considered in developing treatment guidelines. The objectives of the current article are to review the Neuropathic Pain Special Interest Group guidelines for the pharmacological management of neuropathic pain and to provide a brief overview of these recent studies.|*Evidence-Based Medicine[MESH]|Acetamides/therapeutic use[MESH]|Amines/therapeutic use[MESH]|Analgesics, Opioid/therapeutic use[MESH]|Analgesics/*therapeutic use[MESH]|Anesthetics, Local/therapeutic use[MESH]|Antidepressive Agents/*therapeutic use[MESH]|Cyclohexanecarboxylic Acids/therapeutic use[MESH]|Gabapentin[MESH]|Humans[MESH]|Lacosamide[MESH]|Neuralgia/*drug therapy/prevention & control[MESH]|Practice Guidelines as Topic[MESH]|Pregabalin[MESH]|Randomized Controlled Trials as Topic[MESH]|Selective Serotonin Reuptake Inhibitors/therapeutic use[MESH]|gamma-Aminobutyric Acid/analogs & derivatives/therapeutic use[MESH] |